Title:Strategic Combination Therapies for Ovarian Cancer
Volume: 20
Issue: 8
Author(s): Xinran Li, Angel S.N. Ng, Victor C.Y. Mak, Karen K.L. Chan, Annie N.Y. Cheung and Lydia W.T. Cheung*
Affiliation:
- Li Ka Shing Faculty of Medicine, School of Biomedical Sciences, The University of Hong Kong, Pok Fu Lam,Hong Kong
Keywords:
Chemotherapy, combination treatment, immunotherapy, ovarian cancer, targeted therapy, poly (ADP-ribose) polymerase
inhibitors.
Abstract: Ovarian cancer remains the leading cause of gynecologic cancer-related deaths among
women worldwide. The dismal survival rate is partially due to recurrence after standardized debulking
surgery and first-line chemotherapy. In recent years, targeted therapies, including antiangiogenic
agents or poly (ADP-ribose) polymerase inhibitors, represent breakthroughs in the treatment
of ovarian cancer. As more therapeutic agents become available supplemented by a deeper understanding
of ovarian cancer biology, a range of combination treatment approaches are being actively
investigated to further improve the clinical outcomes of the disease. These combinations,
which involve DNA-damaging agents, targeted therapies of signaling pathways and immunotherapies,
simultaneously target multiple cancer pathways or hallmarks to induce additive or synergistic
antitumor activities. Here we review the preclinical data and ongoing clinical trials for developing
effective combination therapies in treating ovarian cancer. These emerging therapeutic modalities
may reshape the treatment landscape of the disease.